Current Funding Opportunities Update

Read in Browser Current Funding Opportunities Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes Biostatistics Research Center (U01 Clinical Trial Not Allowed) 07/14/2021 03:55 PM EDT This FOA invites applications for a Biostatistics Research Center to participate in a clinical consortium to better understand youth-onset type 2 diabetes. A separate FOA (RFA-DK-21-002) invites Clinical Centers to recruit a cohort of early pubertal youth at risk for developing type 2 diabetes and study them through puberty. The ultimate goals of this consortium will be to 1) develop more precise prediction of which individuals are truly at risk for developing youth-onset T2D and identify determinants of progression from prediabetes to T2D so that, ultimately, targeted prevention approaches can be developed and tested; and 2) increase understanding of the physiologic drivers of youth-onset T2D to guide development of more effective strategies to achieve glycemic control and preserve beta cell function. Barbara Linder, M.D., Ph.D. | RFA-DK-21-003 Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes Clinical Centers (U01 Clinical Trial Not Allowed) 07/14/2021 03:55 PM EDT The purpose of this FOA is to create a clinical consortium to recruit a cohort of early pubertal youth at risk for developing type 2 diabetes and study them through puberty. The ultimate goal of this undertaking will be to 1) develop more precise prediction of which individuals are truly at risk for developing youth-onset T2D and identify determinants of progression from prediabetes to T2D so that, ultimately, targeted prevention approaches can be developed and tested; and 2) increase understanding of the physiologic drivers of youth-onset T2D to guide development of more effective strategies to achieve glycemic control and preserve beta cell function. Barbara Linder, M.D., Ph.D. | RFA-DK-21-002 Continuation of The Collaborative Islet Transplantation Registry (U01 Clinical Trial Not Allowed) 07/14/2021 03:44 PM EDT This FOA invites applications for continuation of the Collaborative Islet Transplantation Registry (CITR). Since 2001, this Registry has compiled and analyzed islet transplantation data with the intent to capture all clinical activity in North America as well as additional sites in other countries. Currently, data on both allo- and autotransplantation are collected. The registry will collect data and develop and maintain sophisticated databases to be used by the research community for publications and presentations. CITR will also prepare an annual report available to the public summarizing outcomes of islet transplantation and trends over time as well as conduct an annual CITR meeting for contributing sites. Collection and analysis of this information will contribute to identifying risk factors and key safety and efficacy determinants of successful therapy of islet transplantation as a treatment for patients with type 1 diabetes and pancreatectomy. Peter J. Kozel, Ph.D. | RFA-DK-21-013 Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required) 07/13/2021 05:58 PM EDT The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seeks highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Applications submitted in response to this bi-phasic, milestone-driven cooperative agreement FOA are expected to propose highly innovative projects with a focus on solutions to widely-recognized issues in the development of safe and effective RM therapies. Of particular interest are projects using RM products that have undergone appropriate product development and pre-clinical studies and have demonstrated readiness to advance into clinical trials. This FOA seeks Phase I and beyond clinical trial applications that present a strong scientific rationale for the proposed clinical trial and a comprehensive scientific and operational plan. Trials must be relevant to the research mission of one or more participating NIH Institutes and Centers and meet the NIH definition of a clinical trial (see NOT-OD-15-015). Applications are expected to include plans for project management, participant recruitment and retention, performance milestones, conduct of the trial, and dissemination of results. Before the time of award and if applicable, successful applicants must obtain an Investigational New Drug (IND) authorization or Investigational New Device Exemption (IDE) approval to administer the product to humans. Successful applicants proposing the use of adult stem cells as a clinical intervention will be asked to make available representative samples of the source stem cell and clinical-grade stem cell-derived product for in-depth and independ Ivonne Schulman, M.D. | RFA-HL-22-014 PHS 2021-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) 07/08/2021 05:31 PM EDT This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH and CDC awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2021-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Daniel Gossett, Ph.D. | PA-21-260 PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) 07/08/2021 05:29 PM EDT This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH) invites eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2021-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement does not accept clinical trials. Daniel Gossett, Ph.D. | PA-21-262 PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) 07/08/2021 05:28 PM EDT This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2021-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials. Daniel Gossett, Ph.D. | PA-21-259 Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions Knowledgebase Management Center (U24 Clinical Trial Not Allowed) 07/06/2021 07:33 PM EDT This Funding Opportunity Announcement (FOA) invites U24 cooperative agreement applications for a Knowledge Management Center (KMC) to support grantees engaged in identifying and characterizing microbial metabolites for building a knowledgebase. A companion FOA [PAR-21-253, Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed)] invites applications for identifying and characterizing microbial metabolites that will be used by this KMC to create a knowledgebase on microbial metabolites that is accessible to the research community. Padma Maruvada, Ph.D. | RFA-DK-21-014 Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed) 07/06/2021 07:33 PM EDT The purpose of the Funding Opportunity Announcement is to invite applications to identify and characterize microbial metabolites that will establish causal associations between microbial metabolism and host health and disease. Data acquired through this initiative will be used to create a knowledgebase of microbial metabolites and associated functions that will be provided to the research community. Development of the database and knowledge portal for these awards will be supported under a separate initiative: RFA-DK-21-014, namely Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions Knowledgebase Management Center U24 Resource-Related Research Projects Cooperative Agreements. Padma Maruvada, Ph.D. | PAR-21-253 HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional) 07/06/2021 07:19 PM EDT The goals of this program are to support locally relevant research in critical areas of HIV-associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) Institutions, to enhance research capacity, and build a network of researchers both within and across LMICs to address this critical burden. This initiative is expected to stimulate new research on the interplay between HIV and development of NCDs in persons living with HIV (PLWH), including exploratory studies to uncover the extent to which HIV infection influences the etiopathogenesis of the NCDs; and to identify and develop appropriate approaches for effective diagnosis, prevention, therapeutic interventions and integrated clinical care for PLWH with the comorbid conditions. Applicants should develop their studies in keeping with the NIH HIV/AIDS Research Priorities ( https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html; https://www.oar.nih.gov/hiv-policy-and-research/research-priorities). Research teams should contain an appropriate mix of expertise to accomplish the proposed studies, including partnerships between HIV and NCD researchers who can initiate new ideas and determine feasibility of novel approaches to understand and reduce the long-term suffering from the comorbid disorders. Applicants will also be asked to address the needs of collaborating LMIC institutions to develop capacity for carrying out research in this field. U.S. and LMIC investigators are eligible to apply for collaborative projects to be done at LMIC sites; however, a U.S. investigator must apply together with an LMIC investigator. LMICs are defined by the World Bank classification system according to Gross National Income (GNI) per capita as low-income, lower-middle-income, and upper-middle-income (http://data.worldbank.org/about/country-classifications/country-and-lending-groups). Peter Perrin, Ph.D. | PAR-21-246   View All Funding Opportunities

To unsubscribe, update your password, or change your email address visit our Subscriber Preference Page. For any questions or problems with this subscription service, please visit the Subscriber Help Center.

---

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 Information Way, Bethesda, MD 20892 · 1-800-860-8747